Hadassah Heart Specialists Reveal Detrimental Effect of Thyroid Imbalance on Heart Failure Patients
A study by the Hadassah Medical Organization's heart specialists has revealed that increased levels of thyroid-stimulating hormone (TSH) are correlated with "worse clinical outcome" in patients suffering from heart failure. "Thyroid imbalance," they report, "confers significant risk in heart failure and warrants attention."
While it has been known that thyroid dysfunction affects cardiac function and is a risk factor for heart failure, the scientists report, "data regarding the clinical significance of TSH levels alone as a predictor of outcome in patients with heart failure is sparse." Their study evaluated the significance of TSH on clinical outcome in a large cohort of patients with chronic heart failure.
With 500 beds, 19 stories (five underground) and state-of-the-art technical equipment, the Tower is the most advanced medical facility in the Middle East.
Study findings reveal that both a high and a low TSH level are associated with an increased mortality rate. In addition, TSH was also an independent predictor of death and cardiac-related hospitalization. For those patients not receiving thyroid hormone treatment, "TSH was an even stronger predictor of mortality." At the same time, increasing TSH levels above normal were "independently associated with increased mortality and cardiac-related hospitalizations."
The study, entitled "The Effect of Thyroid Function on Clinical Outcome in Patients with Heart Failure," was published in the February 2014 issue of the European Journal of Heart Failure (Volume 16, Issue 2).
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>